MedTech
Nasdaq-listed Icon unveils $2bn bond offering
Headquartered in Dublin, the company is forecasting full-year revenues of between $8.4bn to $8.7bn
Icon, the Nasdaq-listed clinical trials group, has announced a $2 billion (€1.86 billion) bond offering.
Headquartered in Dublin and employing approximately 41,150 people across 54 countries Icon is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries.
